A Neuroimaging Biomarker for Asymptomatic Alzheimer ’s Disease

Lea Grinberg, MD, PhD
University of California, San Francisco (San Francisco, CA)

Collaborators

Edson Amaro Jr., MD, PhD
Universidade de São Paulo
Helmut Heinsen, MD, PhD
Universidade de São Paulo (São Paulo, Brazil)
Duygu Tosun, PhD
Universidade de São Paulo
Daniela Ushizima, PhD
Lawrence Berkeley National Laboratory (Berkeley, CA)
Year Awarded:
2017
Grant Duration:
July 1, 2017 to June 30, 2021
Disease:
Alzheimer's Disease
Award Amount:
$300,000
Grant Reference ID:
A2017560S
Award Type:
Standard
Award Region:
US Northwestern

This grant is made possible in part by support from The Carl and Judy Moore Charitable Foundation.

Lea Grinberg, MD, PhD

My beloved paternal grandmother developed Alzheimer’s, and I saw her brightness disappearing in front of my eyes for a painful period of 20 years.

Read More

Novel Locus Ceruleus-based Imaging Volumetry to Track Prodromal Alzheimer’s

Summary

For screening and clinical management, and for clinical trials, it would be extremely useful to be able to monitor the pathological progression of Alzheimer’s disease (AD), especially during the decades preceding the onset of clinical symptoms when AD spreads silently in the brain. To date, postmortem examination remains the only tool to confirm and stage AD diagnosis. We found that a tiny brainstem nucleus, the locus ceruleus (LC), is especially vulnerable and earliest-damaged in AD. Furthermore, investigating postmortem tissue, we found evidence that in AD patients, the LC showed linear and progressive shrinkage. We will develop a histologically-validated clinical MRI [magnetic resonance imaging] template for detecting LC shrinkage. This should allow us to track AD progression on a case-by-case in individuals and permit intervention before a substantial amount of neurons have died. LC volumetry is potentially more scalable and economical than other potential AD biomarkers, and could be developed for longitudinal screening. Having such a method in place would in turn make it more feasible to identify and triage high-risk candidates for less accessible, more expensive, and more invasive studies, including PET [positron emission tomography] scans and spinal taps.

Details

New ways of monitoring the progression of AD lesions remain elusive, and postmortem examination remains the only tool to confirm and stage AD diagnosis. Based on our findings in postmortem human brains, we are developing MRI-based biomarkers for noninvasively detecting AD-associated pathology progression in living patients. These new probes will identify brain structural damage years before clinical AD symptoms, at single patient level, using clinical 3 Tesla (3T) MRI scans, which is twice as strong as current high-strength MRI imaging and allows for exceptional clinical detail.  [Tesla (T) is the unit of measurement quantifying the strength of a magnetic field, and until now, the high-field standard was 1.5T. Integrated results from 3T MRI imaging will culminate in the Prodromal Alzheimer’s Disease Detection System, which are automated systems for accurate brain image analysis that will lay the groundwork to deploy services to non-specialized centers.

The project has three tangible and clear deliverables:

  • Histology-centric: Histology-based 7T MRI maps of LC nucleus. Methods: We will create histology-validated MRI algorithms using modern landmark- and contrast-based registration that simultaneously increases spatial resolution and angular resolution from 3D reconstruction from high-resolution brain architectonics, detected by postmortem whole-brain histological analysis, with voxel-wise correspondence to postmortem 7T (d)/MRI data.
  •  MRI-centric: Translate the 7T into clinical 3T MRI templates. Methods: The 7T maps will be harmonized with 3T scanners, which are more standard in U.S. hospitals, improving scalability and accessibility. We will generate templates by a step-wise strategy, using voxel-wise correspondence between postmortem in cranio 7T and 3T MRIs, and then to antemortem 3T MRIs of the same subjects.
  • Precision-centric: Test specificity and sensibility of the biomarkers, their correlation with other AD markers, and their accuracy as a group and as a single readout. Methods:  We will apply the frameworks developed in deliverable #2 to detect LC changes in large, de-identified, longitudinal imaging datasets focusing on brain aging/dementia for testing sensibility and population-based for testing specificity.

Our project innovates in many ways, including:

  • Unique, highly specialized expertise of our collaborative team, which includes radiologists, anatomists and data scientists, complements my specialty in neuropathology;
  • Use of supercomputers, the only kind of computer able to process high-resolution histology reconstruction (eg, 80 GB for whole-brain histology vs. 10 MB for brain MRI 3D reconstruction);
  • Innovative proposed step-wise approach including postmortem brains and corresponding MRI will be used to create a histologically-validated algorithm for high-precision mapping of the LC in 3T MRI, guaranteeing the accuracy of the results and direct translation to clinical practice; and
  • Use of deep learning computing methods to power the accuracy of our algorithms and minimize false negatives. 

Our algorithm/biomarker will enable longitudinal, sensitive, clinical MRI measurements to track individuals' neuropathological progression. This could ultimately allow detection of AD at much earlier stages and permit intervention before neurons in affected brain regions have become irretrievably damaged. Our proposed biomarker is anticipated to be highly sensitive and will provide a scalable, highly cost-effective, and widely accessible screening tool because MRI equipment is widely available and its cost continues to drop. Results will guide clinical decisions, and narrow down the subject population requiring more expensive PET scans and invasive spinal tap. Also, early diagnosis provided by our biomarker will translate into early intervention and lower care-associated costs.

About the Researcher

Dr. Grinberg is a neuropathologist with an interest in brain aging and associated disorders. Currently, she is an associate professor of neurology and pathology at the University of California in San Francisco; an affiliated professor of pathology at the University of Sao Paulo – Brazil; a visiting scientist in the Computer Department at the Lawrence Berkeley National Labs; and head of the Human Validation Core for the NIH-funded Center Without Walls for tau biology. Among Dr. Grinberg’s contributions to the dementia field are the identification of brainstem nuclei as the earliest structures affected in AD and the translation of these findings to diagnosis and treatment development; use of high-resolution histology and sophisticated computing tools for validating multimodal neuroimaging findings; and participation in several international neuropathological consortia for establishing neuropathological criteria for neurodegenerative diseases and vascular dementia.

Personal Story

I have wanted to understand why our brains develop dementia since I was a child. At that time, my plan was to develop a way to transplant brains and replace damaged brains with healthy ones. As the years passed, my beloved paternal grandmother developed Alzheimer’s, and I saw her brightness disappearing in front of my eyes for a painful period of 20 years, despite all kinds of treatments we tried to stop the disease. I went to medical school knowing I wanted to dedicate my life to dementia research and chose to become a pathologist with the understanding that I had to be able to look directly inside the brain to figure out what was going wrong. I founded a prolific brain bank and after analyzing this vast collection, it became clear to me that by the time the first symptoms of AD manifest, the brain has already suffered considerable and irreversible damage. I then focused my research on finding which areas of the brain degenerated first in AD, and how, and I finally could show that small inner brain structures overlooked in the classical descriptions of AD proved to be the most vulnerable and early affected regions. As the daughter of a software developer, I was exposed to advanced computer methods from my early childhood. It gave me the tools to incorporate advanced computing methods in my research repertoire from the beginning.

This grant from the BrightFocus Foundation is allowing me to put together all the methods my collaborators and I developed in the last decade to create what we believe will be effective and economical biomarkers to monitor AD progression. I envision this biomarker as the equivalent to AD of screening mammograms to breast cancer. I have no words to express my gratitude to the BrightFocus Foundation to make it happen.

Besides science, I love to read and to travel. One of my biggest pleasures is to see my own kids sharing my passions!

Publications

Resende EPF, Nolan AL, Petersen C, Ehrenberg AJ, Spina S, Allen IE, Rosen HJ, Kramer J, Miller BL, Seeley WW, Gorno-Tempini ML, Miller Z, Grinberg LT. Language and spatial dysfunction in Alzheimer disease with white matter thorn-shaped astrocytes: Astrocytic tau, cognitive function, and Alzheimer disease. Neurology. 2020 Jan 30. pii: 10.1212/WNL.0000000000008937. doi: 10.1212/WNL.0000000000008937. [Epub ahead of print] PubMed PMID: 32001514 PubMed Icon Google Scholar Icon

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.